Auris Medical Holding AG (NASDAQ:EARS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “

EARS has been the topic of a number of other reports. JMP Securities downgraded Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Needham & Company LLC upped their price target on Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, August 19th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $12.00 price target on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $8.88.

Auris Medical Holding AG (NASDAQ:EARS) opened at 1.73 on Thursday. Auris Medical Holding AG has a 52-week low of $1.55 and a 52-week high of $7.96. The company’s 50-day moving average price is $2.09 and its 200 day moving average price is $3.39. The stock’s market capitalization is $59.39 million.

Institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. purchased a new position in Auris Medical Holding AG during the second quarter valued at about $277,000. TFS Capital LLC increased its position in Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock valued at $160,000 after buying an additional 5,762 shares during the last quarter. Finally, Bellevue Group AG purchased a new position in Auris Medical Holding AG during the first quarter valued at about $7,897,000. 30.95% of the stock is currently owned by hedge funds and other institutional investors.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.